苏黄止咳胶囊治疗成人咳嗽变异性哮喘有效性与安全性系统评价

Efficacy and Safety of Suhuang Zhike Capsules in the Treatment of Adult Patients with Cough-Variant Asthma:A Systematic Review

目的系统评价苏黄止咳胶囊治疗咳嗽变异性哮喘(CVA)的有效性及安全性。方法采用计算机检索PubMed、The Cochrane Library、中国生物医学文献数据库(CBM)、中国知网、维普、万方数据库及中国临床试验注册中心有关苏黄止咳胶囊治疗CVA的临床随机对照试验,检索时限为自建库起至2023年4月1日,采用Cochrane 5.2.0系统手册进行文献质量评价,采用RevMan 5.4软件进行统计学分析。结果共纳入28篇文献,涉及CVA患者2571例。其中,观察组(苏黄止咳胶囊联合常规西药治疗)1303例,对照组(常规西药治疗)1268例。Meta分析结果显示,观察组的治疗总有效率[OR=4.46,95%CI(3.39,5.88),P<0.00001],对呼气峰流量[MD=10.52,95%CI(9.00,12.04),P<0.00001],第1秒用力呼气容积[MD=0.52,95%CI(0.47,0.56),P<0.00001],咳嗽评分[MD=-0.40,95%CI(-0.43,-0.36),P<0.00001],用力肺活量[MD=0.54,95%CI(0.49,0.59),P<0.00001],白细胞介素6[MD=-3.90,95%CI(-4.37,-3.44),P<0.00001]的改善效果均显著优于对照组。两组均未报道严重不良反应,轻微不良反应无需停药即可缓解。结论苏黄止咳胶囊治疗CVA的有效性较好,可改善患者的第1秒用力呼气容积、咳嗽症状、用力肺活量、白细胞介素6水平,且安全性良好。

Objective To systematically review the efficacy and safety of Suhuang Zhike Capsules in the treatment of cough-variant asthma(CVA).Methods The randomized controlled trials(RCTs)of Suhuang Zhike Capsules in the treatment of CVA in the PubMed,The Cochrane Library,CBM,CNKI,VIP,WanFang database,and China Clinical Trial Registration Center from their inception to April 1,2023 were searched and screened based on inclusion criteria.The Cochrane 5.2.0 system manual was used to evaluate the quality of the literature,and RevMan 5.4 software was used for statistical analysis.Results A total of 28 studies were included,involving 2571 patients with CVA,including 1303 patients in the observation group(treated with Suhuang Zhike Capsules combined with conventional Western medicine)and 1268 patients in the control group(treated with conventional Western medicine).Meta-analysis results showed that the total treatment effective rate[OR=4.46,95%CI(3.39,5.88),P<0.00001],and the improvement of peak expiratory flow[MD=10.52,95%CI(9.00,12.04),P<0.00001],forced expiratory volume in the first second[MD=0.52,95%CI(0.47,0.56),P<0.00001],cough score[MD=-0.40,95%CI(-0.43,-0.36),P<0.00001],forced vital capacity[MD=0.54,95%CI(0.49,0.59),P<0.00001],and interleukin-6[MD=-3.90,95%CI(-4.37,-3.44),P<0.00001]in the observation group was significantly better than that in the control group.No serious adverse reactions were reported in the two groups,and mild adverse reactions could be relieved without stopping the medication.Conclusion Suhuang Zhike Capsules are effective and safe in the treatment of CVA,which can improve the patients'forced expiratory volume in the first second,cough symptoms,forced vital capacity,and interleukin-6 levels.